Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release its third quarter earnings report before the opening bell on Friday, Oct. 30.
Analysts expect the Tarrytown, New York-based company to report quarterly earnings of $16.19 per share, up from $11.83 per share in the year-ago period. The consensus estimate for REGN’s quarterly revenue is $4.56 billion. It reported $3.75 billion last year, according to Benzinga Pro.
On Oct. 26, Regeneron Pharmaceuticals announced that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb for U.S. preparedness against Ebola disease.
Shares of Regeneron Pharmaceuticals rose 0.7% to close at $818.77 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- TD Cowen analyst Tyler Van Buren maintained the stock with a Buy rating and raised the price target from $960 to $980 on Oct. 21, 2026. This analyst has an accuracy rate of 55%.
- UBS analyst Trung Huynh upgraded the stock from Neutral to Buy and increased the price target from $660 to $978 on Oct. 15, 2026. This analyst has an accuracy rate of 74%.
- RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform rating and boosted the price target from $737 to $810 on Oct. 8, 2026. This analyst has an accuracy rate of 54%.
- Truist Securities analyst Gregory Renza maintained a Buy rating and boosted the price target from $772 to $780 on Oct. 7, 2026. This analyst has an accuracy rate of 64%.
- Morgan Stanley analyst Matthew Harrison maintained an Equal-Weight rating and raised the price target from $758 to $779 on Oct. 7, 2026. This analyst has an accuracy rate of 64%.
Considering buying REGN stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments